Systematic review / meta-analysis / 2015
Evidence for the clinical effectiveness of pomegranate products in cancer treatment is poor due to poor study quality.
Researchers conducted two systematic reviews evaluating the effectiveness and safety of pomegranate products for cancer treatment, alongside product compositional analyses. Four clinical studies investigating three pomegranate products were identified, with one study considered inappropriate due to low polyphenol content. The evidence of clinical effectiveness was poor because study quality was poor. While the doses used in clinical studies showed no safety concerns, pomegranate preparations may induce synthetic drug metabolism through liver enzyme activation.
- Study type
- Two systematic reviews and product composition analysis
- Who was studied
- Participants across 4 identified clinical studies
- What was measured
- Effectiveness in cancer treatment and safety/toxicity of pomegranate products
THE PAPER
Efficacy and safety of pomegranate medicinal products for cancer.
Vlachojannis C, Zimmermann BF, Chrubasik-Hausmann S. Evid Based Complement Alternat Med, 2015.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.